February 2026 – Mechanistic and Pharmacological Characterization of IGF1R kinase inhibitor

Work performed as part of the doctoral studies of C

February 7, 2026 sdfca

Work performed as part of the doctoral studies of C.M.S. alphaherpesvirus 1 (subtypes 1.1, 1.2a, and 1.2b), type 5 (subtypes 5a, 5b, and 5c), and

Progesterone Receptors

== == Issue == SARSCoV2 variants continue steadily to emerge, which escape antibodies administered in the antibodies or clinic that are elicited by vaccines and organic infection

February 6, 2026 sdfca

== == Issue == SARSCoV2 variants continue steadily to emerge, which escape antibodies administered in the antibodies or clinic that are elicited by vaccines and

Progesterone Receptors

Cells were treated with anti-fibre Abdominal (1:500) at 4C for 60min

February 3, 2026 sdfca

Cells were treated with anti-fibre Abdominal (1:500) at 4C for 60min. CAR, during secondary infection, observing that fibre proteins spread from infected cells to adjacent

Enzyme Substrates / Activators

Stained, dehydrated slides had been installed in Vectamount (H-5000, Vector Laboratories), dried out and scanned with Mirax (Zeiss)

February 2, 2026 sdfca

Stained, dehydrated slides had been installed in Vectamount (H-5000, Vector Laboratories), dried out and scanned with Mirax (Zeiss). == CSF Proteomics and Data Evaluation ==

Other Wnt Signaling

== Schematic representation of the dose regimen used for immune checkpoint inhibitors(ICIs): (A) a-PD-1 was intravenously (iv) administered to TC-1 tumor-bearing mice; (B) a-PD-L1 was iv injected to B16-OVA tumor-bearing mice

February 1, 2026 sdfca

== Schematic representation of the dose regimen used for immune checkpoint inhibitors(ICIs): (A) a-PD-1 was intravenously (iv) administered to TC-1 tumor-bearing mice; (B) a-PD-L1 was

Month: February 2026

﻿Work performed as part of the doctoral studies of C

﻿== == Issue == SARSCoV2 variants continue steadily to emerge, which escape antibodies administered in the antibodies or clinic that are elicited by vaccines and organic infection

﻿Cells were treated with anti-fibre Abdominal (1:500) at 4C for 60min

﻿Stained, dehydrated slides had been installed in Vectamount (H-5000, Vector Laboratories), dried out and scanned with Mirax (Zeiss)

﻿== Schematic representation of the dose regimen used for immune checkpoint inhibitors(ICIs): (A) a-PD-1 was intravenously (iv) administered to TC-1 tumor-bearing mice; (B) a-PD-L1 was iv injected to B16-OVA tumor-bearing mice

Work performed as part of the doctoral studies of C

== == Issue == SARSCoV2 variants continue steadily to emerge, which escape antibodies administered in the antibodies or clinic that are elicited by vaccines and organic infection

Cells were treated with anti-fibre Abdominal (1:500) at 4C for 60min

Stained, dehydrated slides had been installed in Vectamount (H-5000, Vector Laboratories), dried out and scanned with Mirax (Zeiss)

== Schematic representation of the dose regimen used for immune checkpoint inhibitors(ICIs): (A) a-PD-1 was intravenously (iv) administered to TC-1 tumor-bearing mice; (B) a-PD-L1 was iv injected to B16-OVA tumor-bearing mice